Efficacy and Safety of Lianhuaqingwen Capsules for the Prevention of Coronavirus Disease 2019: A Prospective Open-Label Controlled Trial

Table 5

Comparison of demographic data and general conditions of subjects with a positive nucleic acid test.

Variables		LH group; N = 3	Control group; N = 10	value
Age, years (median (IQR))		44.67 (41.00–48.00)	41.30 (27.00–63.00)	0.6726
Age group	12–45	2 (66.67)	6 (60.00)	1.0000
	46–70	1 (33.33)	4 (40.00)
	>70	0 (0.00)	0 (0.00)
Gender	Male, N (%)	3 (100.00)	1 (10.00)	0.0140
Drug combinations	Yes, N (%)	0 (0.00)	0 (0.00)
Contact status	Close contacts, N (%)	2 (66.67)	4 (40.00)	0.5594
	Secondary close contacts, N (%)	1 (33.33)	6 (60.00)
Contact form	Living together, N (%)	0 (0.00)	0 (0.00)	0.2308
	Shared the same confined space, N (%)	3 (100.00)	5 (50.00)
	Dined together, N (%)	0 (0.00)	0 (0.00)
	Daily conversation, N (%)	0 (0.00)	0 (0.00)
	Rode in the same vehicle, N (%)	0 (0.00)	0 (0.00)
	Live in the same village, N (%)	0 (0.00)	0 (0.00)
	Via medical care, N (%)	0 (0.00)	5 (50.00)
	Others, N (%)	0 (0.00)	0 (0.00)